FIELD: pharmaceuticals.
SUBSTANCE: invention relates to the field of pharmacology and medicine and is aimed at treating diseases caused by betacoronaviruses, including SARS-CoV-2. Described is an application of a derivative of 1,3,5-triazine-2,4-diamine by the general formula I, wherein R1 and R2 constitute a substituent selected from hydrogen; an alkyl (C1-C10) of an unbranched or branched structure; an aryl without substituents or substituted in positions 2,3,4,5,6; a hetaryl constituting a nitrogen-, and/or sulphur-, and/or oxygen-containing five- or six-membered heterocycle; R3 constitutes a substituent selected from hydrogen; or an alkyl (C1-C10) of an unbranched or branched structure; or an aryl without substituents or substituted in positions 2,3,4,5,6; or a hetaryl, wherein the hetaryl is a nitrogen-, and/or sulphur-, and/or oxygen-containing five- or a six-membered heterocycle; or an alkylNH, wherein the alkyl(C1-C10) is of an unbranched or branched structure; or an arylNH-, wherein the aryl is without substituents or is substituted in positions 2,3,4,5,6; or a hetarylNH-, wherein the hetaryl constitutes a nitrogen-, and/or sulphur-, and/or an oxygen-containing five- or six-membered heterocycle; or pyrrolidine-1-yl, piperidine-1-yl, morpholine-4-yl-, piperazine-1-yl-, homopiperazine-1-yl-, tetrahydroquinoline-1-yl-, tetrahydroisoquinoline-2-yl-, hexamethyleneiminyl; or R4CH2-, wherein R4 is selected from an alkyl (C1-C10) of an unbranched or branched structure; an aryl without substituents or substituted in positions 2,3,4,5,6; a hetaryl, wherein the hetaryl constitutes a nitrogen-, and/or sulphur-, and/or oxygen-containing five- or six-membered heterocycle; pyrrolidine-1-yl, piperidine-1-yl, morpholine-4-yl-, piperazine-1-yl-, homopiperazine-1-yl-, tetrahydroquinoline-1-yl-, tetrahydroisoquinoline-2-yl, hexamethyleneiminyl for suppressing the replication of betacoronavirus.
EFFECT: ensured effective suppression of the replication of betacoronaviruses, including SARA-CoV-2, at low values of the effective concentration of EC50, low cytotoxicity, and high value of selectivity index.
5 cl, 1 tbl, 7 ex
| Title | Year | Author | Number |
|---|---|---|---|
| APPLICATION OF A TRICYCLIC SULPHUR-CONTAINING DERIVATIVE OF 1,2-DIHYDROQUINOLINE FOR INHIBITING THE REPLICATION OF BETACORONAVIRUSES, INCLUDING SARS-COV-2 | 2021 |
|
RU2780247C1 |
| APPLICATION OF AN OXYGEN-CONTAINING DERIVATIVE OF 6-HALOQUINOLINE FOR INHIBITING THE REPLICATION OF BETACORONAVIRUSES, INCLUDING SARS-COV-2, AND METHOD FOR PRODUCTION THEREOF | 2021 |
|
RU2780245C1 |
| PHARMACEUTICAL COMPOSITION, INCLUDING TRICYCLIC SULFUR-CONTAINING 1,2-DIHYDROQUINOLINE DERIVATIVE FOR INHIBITION OF REPLICATION OF BETA CORONAVIRUSES, INCLUDING SARS-CoV-2, AND METHOD OF ITS USE | 2021 |
|
RU2814434C1 |
| METHOD OF PRODUCING A TRICYCLIC SULFUR-CONTAINING DERIVATIVE OF 1,2-DIHYDROQUINOLINE FOR INHIBITING REPLICATION OF BETA-CORONAVIRUSES, INCLUDING SARS-CoV-2 | 2021 |
|
RU2819783C1 |
| METHOD FOR PREPARING A THIO DERIVATIVE OF PYRROLIDINE-2,5-DIONE WITH A QUINAZOLINE FRAGMENT | 2021 |
|
RU2807057C2 |
| 5-[4-(1,3-BENZOTHIAZOL-2-YL)PHENYL]-10,15,20-TRIS(1-METHYLPYRIDINIUM-3-YL)PORPHYRIN TRIIOODIDE, SHOWING THE BINDING PROPERTY OF THE SARS-CoV-2 VIRUS SPIKE PROTEIN | 2021 |
|
RU2773397C1 |
| 5,15-BIS(4'-BIS-L-TYROSINYLAMIDOPHENYL)-10,20-BIS(N-METHYLPYRIDINIUM-3'-YL)PORPHIN DIOODIDE, SHOWING THE PROPERTY OF BINDING SARS-COV-2 VIRUS S-PROTEIN | 2022 |
|
RU2784940C1 |
| SET OF SYNTHETIC OLIGODEOXYRIBONUCLEOTIDES AND A METHOD FOR QUANTIFYING THE VIRAL LOAD OF SARS-CoV-2 IN TISSUES OF VARIOUS ORGANS BY QUANTITATIVE POLYMERASE CHAIN REACTION IN REAL TIME | 2021 |
|
RU2761358C1 |
| APPLICATION OF N,N'-BIS-(2,3-BUTADIENYL)-1,4-DIAMINOBUTANE DIHYDROCHLORIDE (MDL72.527) FOR SUPPRESSING REPLICATION OF SARS-COV-2 VIRUS | 2020 |
|
RU2761565C1 |
| METHOD FOR PREVENTIVE TREATMENT OF CORONAVIRUS INFECTION | 2020 |
|
RU2777462C2 |
